Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Primary relevance to vitamin D Vitamin D is a stated subject of this paper.

Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.

Why this paper is included

Supporting source evidence:

The aim of the current study was to explore the potential mechanisms underlying these associations by determining whether low vitamin D concentrations are associated with the development of incident cerebrovascular and neurodegenerative neuroimaging abnormalities.

Source: Abstract. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Participants were selected from the CHS, a large prospective population-based cohort in the US designed to investigate the underlying causes of cardiovascular disease in older men and women.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Vitamin D and Risk of Neuroimaging Abnormalities

Study design awaiting verification · PLoS ONE · 2016

Original publication title

Vitamin D and Risk of Neuroimaging Abnormalities

Thomas J. Littlejohns; Katarina Kos; William E. Henley; Iain A. Lang; Cedric Annweiler; Olivier Beauchet; Paulo H. M. Chaves; Bryan R. Kestenbaum; Lewis H. Kuller; Kenneth M. Langa; Oscar L. Lopez; David J. Llewellyn

© 2016 Littlejohns et al

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

At a glance

What does the authors’ abstract report?

Vitamin D deficiency has been linked with an increased risk of incident all-cause dementia and Alzheimer’s disease. The aim of the current study was to explore the potential mechanisms underlying these associations by determining whether low vitamin D concentrations are associated with the development of incident cerebrovascular and neurodegenerative neuroimaging abnormalities. The population consisted of 1,658 participants aged ≥65 years from the US-based Cardiovascular Health Study who were free from prevalent cardiovascular disease, stroke and dementia at baseline in 1992 to 93.

Serum 25-hydroxyvitamin D (25(OH)D) concentrations were determined by liquid chromatography-tandem mass spectrometry from blood samples collected at baseline. The first MRI scan was conducted between 1991 to 1994 and the second MRI scan was conducted between 1997 to 1999. Change in white matter grade, ventricular grade and presence of infarcts between MRI scan one and two were used to define neuroimaging abnormalities. During a mean follow-up of 5.0 years, serum 25(OH)D status was not significantly associated with the development of any neuroimaging abnormalities. Using logistic regression models, the multivariate adjusted odds ratios (95% confidence interval) for worsening white matter grade in participants who were severely 25(OH)D deficient (<25 nmol/L) and deficient (≥25 to 50 nmol/L) were 0.76 (0.35 to 1.66) and 1.09 (0.76 to 1.55) compared to participants with sufficient concentrations (≥50 nmol/L).

The multivariate adjusted odds ratios for ventricular grade in participants who were severely 25(OH)D deficient and deficient were 0.49 (0.20 to 1.19) and 1.12 (0.79 to 1.59) compared to those sufficient. The multivariate adjusted odds ratios for incident infarcts in participants who were severely 25(OH)D deficient and deficient were 1.95 (0.84 to 4.54) and 0.73 (0.47 to 1.95) compared to those sufficient. Overall, serum vitamin D concentrations could not be shown to be associated with the development of cerebrovascular or neurodegenerative neuroimaging abnormalities in Cardiovascular Health Study participants.

Authors’ abstract

Vitamin D deficiency has been linked with an increased risk of incident all-cause dementia and Alzheimer’s disease. The aim of the current study was to explore the potential mechanisms underlying these associations by determining whether low vitamin D concentrations are associated with the development of incident cerebrovascular and neurodegenerative neuroimaging abnormalities. The population consisted of 1,658 participants aged ≥65 years from the US-based Cardiovascular Health Study who were free from prevalent cardiovascular disease, stroke and dementia at baseline in 1992 to 93.

Serum 25-hydroxyvitamin D (25(OH)D) concentrations were determined by liquid chromatography-tandem mass spectrometry from blood samples collected at baseline. The first MRI scan was conducted between 1991 to 1994 and the second MRI scan was conducted between 1997 to 1999. Change in white matter grade, ventricular grade and presence of infarcts between MRI scan one and two were used to define neuroimaging abnormalities. During a mean follow-up of 5.0 years, serum 25(OH)D status was not significantly associated with the development of any neuroimaging abnormalities. Using logistic regression models, the multivariate adjusted odds ratios (95% confidence interval) for worsening white matter grade in participants who were severely 25(OH)D deficient (<25 nmol/L) and deficient (≥25 to 50 nmol/L) were 0.76 (0.35 to 1.66) and 1.09 (0.76 to 1.55) compared to participants with sufficient concentrations (≥50 nmol/L).

The multivariate adjusted odds ratios for ventricular grade in participants who were severely 25(OH)D deficient and deficient were 0.49 (0.20 to 1.19) and 1.12 (0.79 to 1.59) compared to those sufficient. The multivariate adjusted odds ratios for incident infarcts in participants who were severely 25(OH)D deficient and deficient were 1.95 (0.84 to 4.54) and 0.73 (0.47 to 1.95) compared to those sufficient. Overall, serum vitamin D concentrations could not be shown to be associated with the development of cerebrovascular or neurodegenerative neuroimaging abnormalities in Cardiovascular Health Study participants.

Publication and source details

Original title: Vitamin D and Risk of Neuroimaging Abnormalities

Thomas J. Littlejohns; Katarina Kos; William E. Henley; Iain A. Lang; Cedric Annweiler; Olivier Beauchet; Paulo H. M. Chaves; Bryan R. Kestenbaum; Lewis H. Kuller; Kenneth M. Langa; Oscar L. Lopez; David J. Llewellyn

PLoS ONE · 2016

Competing Interests: The authors have declared that no competing interests exist.

Conceived and designed the experiments: TJL KK WEH DJL. Performed the experiments: TJL WEH DJL. Analyzed the data: TJL WEH DJL. Wrote the paper: TJL KK WEH IAL CA OB PHMC BRK LK KML OLL DJL. Acquisition of the data: BRK LK KML OLL. Interpretation of data for the work: TJL KK WEH IAL CA OB PHMC BRK LK KML OLL DJL.

* E-mail: david.llewellyn@exeter.ac.uk
© 2016 Littlejohns et al2016Littlejohns et alhttps://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.http://dx.doi.org/10.13039/100000957Alzheimer's AssociationNIRG-11-200737Llewellyn David J. http://dx.doi.org/10.13039/100000050National Heart, Lung, and Blood InstituteHHSN268201200036Chttp://dx.doi.org/10.13039/100000050National Heart, Lung, and Blood InstituteHHSN268200800007Chttp://dx.doi.org/10.13039/100000050National Heart, Lung, and Blood InstituteN01 HC55222http://dx.doi.org/10.13039/100000050National Heart, Lung, and Blood InstituteN01HC85079http://dx.doi.org/10.13039/100000050National Heart, Lung, and Blood InstituteN01HC85080http://dx.doi.org/10.13039/100000050National Heart, Lung, and Blood InstituteN01HC85081http://dx.doi.org/10.13039/100000050National Heart, Lung, and Blood InstituteN01HC85082http://dx.doi.org/10.13039/100000050National Heart, Lung, and Blood InstituteN01HC85083http://dx.doi.org/10.13039/100000050National Heart, Lung, and Blood InstituteN01HC85086http://dx.doi.org/10.13039/100000050National Heart, Lung, and Blood InstituteHL080295http://dx.doi.org/10.13039/100000049National Institute on AgingAG023629http://dx.doi.org/10.13039/100000049National Institute on AgingAG20098http://dx.doi.org/10.13039/100000049National Institute on AgingAG15928http://dx.doi.org/10.13039/100000049National Institute on AgingHL084443The Cardiovascular Health Study was supported by contracts HHSN268201200036C, HHSN268200800007C, N01 HC55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, N01HC85086, and grant HL080295 from the National Heart, Lung, and Blood Institute (NHLBI), with additional contribution from the National Institute of Neurological Disorders and Stroke (NINDS). Additional support was provided by AG023629, AG20098, AG15928 and HL084443 from the National Institute on Aging (NIA). A full list of principal CHS investigators and institutions can be found at chs-nhlbi.org. Additional support was also provided by NIRG-11-200737 from the Alzheimer’s Association, the Mary Kinross Charitable Trust, the James Tudor Foundation, the Halpin Trust, the Age Related Diseases and Health Trust, and the Norman Family Charitable Trust (to D.J.L.). This research was supported by the National Institute for Health Research (NIHR) Collaboration for Leadership in Applied Health Research and Care South West Peninsula at the Royal Devon and Exeter NHS Foundation Trust. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. The National Institutes of Health was involved in the original design and conduct of the Cardiovascular Health Study and in the data collection methods.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T16:17:26.058918+00:00

DOI: 10.1371/journal.pone.0154896 · PMC4864237